Novel therapeutic options and drug targets in MS

2012 witnessed important developments for multiple sclerosis, including successful phase III trials of novel oral therapeutics and identification of the potassium channel KIR4.1 as an autoimmune target. Additionally, the lung was highlighted as an important site for immune-cell programming, and the relevance of a TNF receptor variant was clarified. Methner, A. & Zipp, F. Nat. Rev. Neurol. 9, 72-73 (2013); published online 22 January 2013; doi:10.1038/nrneurol.2012.277